<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>c-myc amplification is usually associated with lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> and Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in particular </plain></SENT>
<SENT sid="1" pm="."><plain>We present a case of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with c-myc amplification which was associated with homogenous staining regions (hsr) and double minutes (dmin) </plain></SENT>
<SENT sid="2" pm="."><plain>The administration of GCSF following induction chemotherapy resulted in a marked increase in blast numbers </plain></SENT>
<SENT sid="3" pm="."><plain>The GCSF was stopped and further courses of chemotherapy given, which resulted in complete remission </plain></SENT>
<SENT sid="4" pm="."><plain>The patient relapsed 7 months after diagnosis and failed to go into a second remission with reinduction therapy </plain></SENT>
<SENT sid="5" pm="."><plain>We conclude that c-myc amplification is a rare event in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, but may be associated with chemotherapy resistance and a poor prognosis, are as dmins and hsr </plain></SENT>
<SENT sid="6" pm="."><plain>Growth factors should be used with caution in these patients </plain></SENT>
</text></document>